The Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialisation.
8:30 : REGISTRATION AND WELCOME COFFEE
9:00 : WELCOME ADRESS
Dr Sylvain Perruche, Med’Inn’Pharma, Besançon, FR
Renaud Gaudillière, PMT director
09:15 : KEYNOTE : Designing scalable Cell Therapy operations from day one
Dr Racha Fayad, KPMG, Zurich, CH
9:45 – 12:00 : SESSION #1 « RESEARCH TO PROOF OF CONCEPT »
Chairpersons : Pr John De Vos, CHU Montpellier and Dr Sylvain Perruche, Med’Inn’Pharma, Besançon, FR
09:45 : Engineering iPSC-derived immune cells
Dr Sjoukje van der Stegen, Chan Zuckerberg BioHub, New-York, USA
10:15 : BREAK – EXHIBITION HALL
11:00 : CeBBOc: a case study in Occitanie in building a regional cell-based biotherapy ecosystem
Pr John De Vos, CHU Montpellier, FRA
11:10 : Extracellular vesicles from iPSC-derived MSCs : An innovative biotherapy for osteoarthritis?
Pr Danièle Noël, IRMB, Montpellier, FRA
11:40 : From spontaneous regeneration to cellular engineering: towards iChondrocyte therapy of articular cartilage
Dr Farida Djouad, IRMB, Montpellier, FRA
12:00-14:00 : LUNCH
12:30-14:30 : EXHIBITION HALL – B2B MEETINGS
14:15-14:45 : SYMPOSIUM CYTIVA : Innovation in CAR-T space: Sefia(tm) platform and non-viral gene transfer solutions
Simon Quenneville and Charles Chesnelong
14:45-17:30 : SESSION #2 « PROOF OF CONCEPT TO CLINIC »
Chairpersons : Dr Jessica Gobbo, CTM Inserm Dijon and Dr Céline Elie-Caille, Institute Femto-ST, FR
14:45 : SGC off-the-shelf innovative immunotherapy to treat cancer : from bench to bedside
Dr George Alzeeb, Brenus Pharma, Lyon, FRA
15:15 : Biotherapies based on extracellular vesicles: from research to innovation
Dr Amanda Silva-Brun, CNRS Université Paris Cité, Paris, FRA
15:45 : Invitrogen™ Vivofectamine™ Delivery Solutions: Advancing genetic medicine innovations with Lipid Nanoparticle (LNP) technologies
Jérôme Cabeau, Thermo Fisher Scientific, FRA
15:50 : BREAK – EXHIBITION HALL
16:30 : Nonclinical development of in vivo CAR-T for autoimmune diseases
Dr Ana Bejanariu, Sanofi, Paris, FRA
17:00 : From Bench to Bedside: Regulatory Strategies and Development Tools to Streamline the Transition from Non-
Clinical to Clinical for Emerging Biotechs
PharmD Damia Benchabane, Alira Health, Paris, FRA
17:45-18:45 : OFFICIAL DELEGATION TOUR
17:45-22:00 : POSTER’S SESSION
18:45-22:00 : NETWORKING COCKTAIL
Opening by representative of the President of Grand Besançon Métropole & representative of the President of the Bourgogne
Franche Comté Region
8:15 : WELCOME COFFEE (KURSAAL)
08:45 : KEYNOTE : The 2025 C> Landscape: Pipeline Dynamics and AI Integration
Gavin Vuddamalay, Mabdesign, Lyon, FR
9:15-12:00 : SESSION #3 : Early-Stage Clinical Trials
Chairpersons : Dr Sylvain Perruche, Med’Inn’Pharma and Dr Jean-Luc Schlick, RD-Biotech, Besançon, FR
09:15 : CAR-T cell in autoimmune diseases: from the laboratory to clinical applications
Pr Dominique Farge-Bancel, CRMR MATHEC, Hôpital St-Louis, AP-HP, Université Paris Cité, Paris, FR
09:45 : Translating MSC Exosome Science into Therapy: Preclinical Evidence and First-in-Human Trial for Psoriasis
Pr Sai Kiang Lim, Paracrine Therapeutics, Singapour
10:15 : BREAK- EXHIBITION HALL
11:00 : ATMP release : from phase I to commercial stage
Dr Hélène Nègre, CELLforCURE by SEQENS, Les Ulis, FRA
11:30 : ATMP regulation in the USA: how does it differ from the EU?
Pr Erika Lietzan, University of Missouri-Columbia, Columbia, USA
12:00-14:00 : LUNCH & Exhibition Hall
12:30-13:50 : B2B MEETINGS
14:00-16:30 : SESSION #4 : SCALE-UP AND GO TO MARKET
Chairpersons : Dr Christophe Ferrand and Dr Marina Deschamps, Right Institute, Besançon, FR
14:00 : Journey of India’s First Indigenous CAR-T Therapy
Dr Rahul Purwar, ImmunoACT, Bombay, India
14:30 : Development of a CAR-T production solution : from idea to market
Guillaume Wallart, Cellquest, Besançon, FRA
15:00 : CAR-T therapy for adult ALL: opportunities and challenges
Dr Claire Roddie, Autolus, London, UK
15:30-15:45 : CONCLUSION & END OF CONGRESS
Dr Marina Deschamps, RIGHT Institute, Besançon, FR
Dr Marina DESCHAMPS, Right Institute (Besançon, FR) – Dr Christophe FERRAND, Right Institute (Besançon, FR) – Sylvain PERRUCHE, MedInn Pharma (Besançon, FR) – Pr John De Vos, CHU Montpellier (Montpellier, FR) – Dr Sjoukje van der Stegen, Chan Zuckerberg BioHub (New-York, USA) – Pr Danièle Noël, IRMB (Montpellier, FRA) – Dr Farida Djouad, IRMB (Montpellier, FRA) – Dr Jessica Gobbo, CTM Inserm (Dijon, FR) – Dr Amanda Silva-Brun, CNRS Université Paris Cité (Paris, FR) – PharmD Damia Benchabane, Alira Health, (Paris, FR) – Pr Dominique Farge-Bancel, CRMR MATHEC, Hôpital St-Louis, AP-HP, Université Paris Cité (Paris, FR) – Pr Sai Kiang Lim, Paracrine Therapeutics (Singapour) – Dr Rahul Purwar, ImmunoACT (Bombay, India) – Dr Jo Mountford, Scottish National Blood Transfusion Service (Edinburgh, UK) – Céline ELIE-CAILLE, Institut Femto-ST (Besançon, FR) – Robert TEP, Diaclone Medxbiochemica (Lyon, FR) – Laure DELHON, Mabdesign (Lyon, FR) – Jean-Luc SCHLICK, RD-Biotech (Besançon, FR) – Dr Olivier HUMBEY, IQVIA (Dijon, FR) – Jérémy MAGALON, AP-HM (Marseille, FR) – Sylvie MERCIER, RD-Biotech (Besançon, FR) – Dr Ana BEJANARIU, Sanofi (Paris, FR) – Guillaume WALLART, Cellquest (Besançon, FR) – Dr Hélène NEGRE, Cell For Cure by Seqens (Les Ulis,FR) – Dr Claire RODDIE, Autolus & UCL (Londres, EN) – George ALZEEB, Brenus Pharma (Clermont-Ferrand, FR) – Pr Erika LIETZAN, University of Missouri-Columbia (Columbia, USA) – Racha FAYAD, KPMG (Zurich, CH)
Ana holds a Veterinary License, Master’s, and PhD in Veterinary Medicine from the Faculty of Veterinary Medicine in Iași, Romania. She began her career in France in the pharmaceutical industry, joining Theravectys, a biotech company affiliated with the Institut Pasteur....
En savoir +George Alzeeb is an accomplished cancer researcher specializing in immunotherapy, 3D tumor modeling, and translational oncology. Currently Innovation Manager at Brenus Pharma, he drives the development of cutting-edge therapeutic strategies, including allogeneic immunotherapy. Dr. Alzeeb earned his PhD in Oncology,...
En savoir +Danièle Noël is currently Research Director at Inserm at the Institute for Regenerative Medicine and Biotherapies (IRMB) in Montpellier. She received her PhD in Health Biology from Bordeaux University in 1992. She completed a post-doctoral fellowship at the Institute of...
En savoir +Jessica Gobbo is an accomplished clinician-researcher with a profound specialization in oncology and translational medicine. She works as a researcher in the early-phase clinical trials unit at the Centre Georges-François Leclerc (CLCC) in Dijon and is a key member of...
En savoir +Amanda Silva Brun (PharmD, PhD, Harvard Business School alumna) is a Research Director at CNRS and Université Paris Cité. Her work at the NABI laboratory (UMR8175) and the IVETh industrial integrator focuses on innovative approaches in biotherapy and the bioproduction...
En savoir +Martin Pule is Clinical Senior Lecturer in the Dept. of Haematology at UCL Cancer Institute and Honorary Consultant in Haematology at University College London Hospital. His research is focused on many aspects of genetic engineering of T-cells for cancer treatment,...
En savoir +Farida Djouad is a Research Director at Inserm and leads the "Mechanisms of Regeneration and Therapeutic Applications" group at the Institute of Regenerative Medicine and Biotherapy (IRMB) in Montpellier, France. She obtained her PhD in Biology and Health from the...
En savoir +Dr. van der Stegen is working to genetically engineer stem cell-derived T-cells, cells of the immune system, that will be specifically directed towards attacking cancer cells. If successful, this would lay the foundation for further therapeutic application of the unlimited,...
En savoir +Claire is a Consultant Haematologist at UCLH and Associate Professor in Haematology at UCL with a particular interest in adoptive cell therapies. She completed an Immunotherapy PhD at UCL with Karl Peggs and subsequently undertook a clinician scientist role with...
En savoir +Sai Kiang Lim is a renowned molecular biologist and biochemist who has made significant contributions to the understanding of the underlying molecular and cellular mechanisms of diseases and the development of therapies. She received her Bachelor of Science in Biochemistry...
En savoir +Racha holds a PhD in Oncology and over six years of consulting experience in the life sciences industry. At KPMG, she supports leading global pharmaceutical companies in optimizing advanced therapy access and operational strategies. Prior to joining KPMG, Racha advised...
En savoir +John De Vos is Professor of Embryology, Histology and Regenerative Medicine at the Faculty of Medicine of Montpellier, and head of the Cellular and Tissue Engineering Department of the University Hospital Center (CHU) of Montpellier. His research, at the Research...
En savoir +From the beginning of my career in 2001 at the “Etablissement Français du Sang” (EFS, BFC, Besançon), I became interested in translational research and more particularly to modulate the T cells lymphocyte response, such as T cells involved in host-graft-tumor...
En savoir +Damia Benchabane joined Alira Health with 11 years of Regulatory Affairs experience in the pharmaceutical industry. Damia has worked in start-ups as well as mid-to-large pharmaceutical companies including LFB Biomédicaments, AB Science, Novartis, and GSK. Damia has extensive experience in...
En savoir +Doctor in Immunology, researcher at and former director of the Autoimmunity-Transplantation-Inflammation research team at the INSERM-Univ Franche Comté-EFS Joint Research Unit 1098 RIGHT in Besançon (FR) for the last 10 years, Dr Perruche is now the founder and CEO of...
En savoir +Professor Lietzan focuses her scholarship and teaching primarily in the areas of FDA law (and health law more generally), administrative law, and intellectual property. She brings to her scholarship and teaching eighteen years of private practice experience, eight of them...
En savoir +Professor of Internal Medicine, AP-HP Saint-Louis University Hospital (Paris Cité University, France); Adjunct Professor, McGill University (Canada) Prof. Dominique Farge is a leading expert in stem cell and immune cell therapies for autoimmune diseases. For over 30 years, she has...
En savoir +PhD in molecular and cell therpay, research director at the INSERM-Univ Franche Comté-EFS Joint Research Unit 1098 RIGHT in Besançon (FR), Dr Christophe Ferrand is also the founder of advesya biotech company, a French clinical-stage biotech company founded in 2020....
En savoir +Helene NEGRE, PharmD, PhD, developed her expertise in Cell & Gene Therapy bioproduction through more than 20 years of experience in Advanced Therapy Medicinal Product (ATMPs). Initially, she worked at Pitié-Salpêtrière Hospital (AP-HP) in the Biotherapy department. In 2014, she...
En savoir +Dr. Rahul Purwar is a professor at Department of Biosciences and Bioengineering at IIT Bombay. He holds a Ph.D. in Molecular Medicine from Hannover Medical School, Germany. Dr. Rahul’s professional journey spans various prestigious institutions and roles. He started his...
En savoir +JCM is the Associate Director for Tissues, Cells and Advanced Therapies (TCAT) at the SNBTS and an Honorary Reader at University of Edinburgh. As an experienced experimental haematologist and stem cell biologist Jo’s focus is the assessment, development and translation...
En savoir +